KNTPF (Kintor Pharmaceutical) Stock Based Compensation: $0.00 Mil (TTM As of Dec. 2025)


KNTPF Kintor Pharmaceutical Ltd KNTPF
26 GF Score
Price $0.25
! 3 Warning Signs
View Full Analysis

What is Kintor Pharmaceutical Stock Based Compensation?

Kintor Pharmaceutical KNTPF 26 Stock Based Compensation is $0.00 Mil as of Dec. 2025. GuruFocus rates KNTPF with a GF Score™ of 26/100. The stock has 3 warning signs investors should review.

Kintor Pharmaceutical's Stock Based Compensation for the six months ended in Dec. 2025 was $0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

Kintor Pharmaceutical Stock Based Compensation Related Terms

Kintor Pharmaceutical Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Kintor Pharmaceutical's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kintor Pharmaceutical Stock Based Compensation Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 5.86 13.72 3.22 -1.25 0.05

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
KNTPF
26GF Score
Kintor Pharmaceutical Ltd KNTPF
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kintor Pharmaceutical Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

What does a Stock Based Compensation of $0.00 Mil mean?
Kintor Pharmaceutical (KNTPF) has a Stock Based Compensation of $0.00 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Kintor Pharmaceutical and its competitors.
Is Kintor Pharmaceutical's Stock Based Compensation too high?
Kintor Pharmaceutical's current Stock Based Compensation is $0.00 Mil. Overall, Kintor Pharmaceutical has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's Stock Based Compensation compare to VRTX and REGN?
Kintor Pharmaceutical's Stock Based Compensation of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Kintor Pharmaceutical and its competitors. Kintor Pharmaceutical's current Stock Based Compensation is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current Stock Based Compensation of $0.00 Mil. The current Stock Based Compensation is $0.00 Mil. Kintor Pharmaceutical's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current Stock Based Compensation is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kintor Pharmaceutical Business Description

Other Exchanges 09939:Hong Kong
Address No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
26GF Score

Get the complete analysis for KNTPF

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price